Table of Contents Author Guidelines Submit a Manuscript
International Journal of Dentistry
Volume 2014, Article ID 298945, 7 pages
http://dx.doi.org/10.1155/2014/298945
Clinical Study

Platelet Rich Plasma in the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw: Personal Experience and Review of the Literature

1Division of Maxillofacial & ENT Surgery, Department of Melanoma, Sarcoma and Head and Neck Surgery, Istituto Nazionale Tumori-Fondazione G. Pascale-IRCCS, Via Aniello Falcone 186, 80127 Naples, Italy
2Postgraduate School in Oral Surgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, Via Pansini 5, 80131 Naples, Italy
3Division of Transfusion Medicine, Department of Haematology, Istituto Nazionale Tumori-Fondazione G. Pascale-IRCCS, Via Semmola 1, 80131 Naples, Italy

Received 11 April 2014; Accepted 19 May 2014; Published 10 June 2014

Academic Editor: Giuliano Ascani

Copyright © 2014 F. Longo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Boonyapakorn, I. Schirmer, P. A. Reichart, I. Sturm, and G. Massenkeil, “Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies,” Oral Oncology, vol. 44, no. 9, pp. 857–869, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Green and P. Clézardin, “The molecular basis of bisphosphonate activity: a preclinical perspective,” Seminars in Oncology, vol. 37, supplement 1, pp. S3–S11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Janovská, “Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy,” Acta Medica, vol. 55, no. 3, pp. 111–115, 2012. View at Google Scholar · View at Scopus
  4. M. Tubiana-Hulin, M. Spielmann, C. Roux et al., “Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis,” Critical Reviews in Oncology/Hematology, vol. 71, no. 1, pp. 12–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. M. H. McLeod, P. A. Brennan, and S. L. Ruggiero, “Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review,” The Surgeon, vol. 10, no. 1, pp. 36–42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. R. Santos-Silva, G. A. Belizario Rosa, G. D. Castro Jr., R. B. Dias, A. C. Prado Ribeiro, and T. B. Brandão, “Osteonecrosis of the mandible associated with bevacizumab therapy,” Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology and Endodontology, vol. 115, no. 6, pp. e32–e36, 2013. View at Google Scholar
  7. Y. Fleissig, E. Regev, and H. Lehman, “Sunitinib related osteonecrosis of jaw: a case report,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 113, no. 3, pp. e1–e3, 2012. View at Google Scholar
  8. D. W. Kim, Y. S. Jung, H. S. Park, and H. D. Jung, “Osteonecrosis of the jaw related to everolimus: a case report,” British Journal of Oral and Maxillofacial Surgery, vol. 51, no. 8, pp. e302–e304, 2013. View at Publisher · View at Google Scholar
  9. J. W. Hellstein, “Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs,” The Journal of the American Dental Association, vol. 142, no. 11, pp. 1243–1251, 2011. View at Google Scholar · View at Scopus
  10. J. V. Bagan, Y. Jimenez, J. Murillo et al., “Jaw osteonecrosis associated with bisphos-phonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases,” Oral Oncology, vol. 42, no. 3, pp. 327–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. V. Lobato, A. C. Maurício, J. M. Rodrigues et al., “Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate,” Journal of Plastic, Reconstructive & Aesthetic Surgery, vol. 61, no. 1, pp. 99–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Marx, “Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic,” Journal of Oral and Maxillofacial Surgery, vol. 61, no. 9, pp. 1115–1117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. C. H. Lin, C. S. Liu, and S. W. Lai, “Long-term use oral bisphosphonate-related osteonecrosis of the jaw without dental extraction in elderly: a case report,” Journal of Clinical Gerontology and Geriatrics, vol. 2, no. 1, pp. 30–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Katz, Y. Gong, D. Salmasinia et al., “Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw,” International Journal of Oral & Maxillofacial Surgery, vol. 40, no. 6, pp. 605–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Mast, S. Otto, T. Mücke et al., “Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw,” Journal of Cranio-Maxillofacial Surgery, vol. 40, no. 7, pp. 568–571, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. F. S. O'Ryan, S. Khoury, W. Liao et al., “Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 7, pp. 1363–1372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. O. Nicolatou-Galitis, E. Papadopoulou, T. Sarri et al., “Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 112, no. 2, pp. 195–202, 2011. View at Google Scholar
  18. S. Fedele, S. R. Porter, F. D'aiuto et al., “Non-exposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series,” The American Journal of Medicine, vol. 123, no. 11, pp. 1060–1064, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Otto, C. Schreyer, S. Hafner et al., “Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment,” Journal of Cranio-Maxillofacial Surgery, vol. 40, no. 4, pp. 303–309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Diego, O. D'Orto, D. Pagani et al., “Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 103, no. 3, pp. e1–e5, 2007. View at Google Scholar
  21. R. Weitzman, N. Sauter, E. F. Eriksen et al., “Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006,” Critical Reviews in Oncology/Hematology, vol. 62, no. 2, pp. 148–152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. N. M. McLeod, V. Patel, A. Kusanale, S. N. Rogers, and P. A. Brennan, “Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw,” British Journal of Oral and Maxillofacial Surgery, vol. 49, no. 5, pp. 335–342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Thumbigere-Math, M. A. Sabino, R. Gopalakrishnan et al., “Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 9, pp. 1904–1913, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Cheng, A. Mavrokokki, G. Carter et al., “The dental implications of bisphosphonates and bone disease,” Australian Dental Journal, vol. 50, no. 4, supplement 2, pp. S4–S13, 2005. View at Google Scholar · View at Scopus
  25. D. K. Lam, G. K. Sándor, H. I. Holmes, A. W. Evans, and C. M. L. Clokie, “A review of bisphosphonate-associated osteonecrosis of the jaws and its management,” Journal of the Canadian Dental Association, vol. 73, no. 5, pp. 417–422, 2007. View at Google Scholar · View at Scopus
  26. L. Montebugnoli, L. Felicetti, D. B. Gissi, A. Pizzigallo, G. A. Pelliccioni, and C. Marchetti, “Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 104, no. 4, pp. 473–477, 2007. View at Google Scholar
  27. J. Bagán, J. Blade, J. M. Cozar et al., “Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates,” Medicina Oral, Patologia Oral y Cirugia Bucal, vol. 12, no. 4, pp. E336–E340, 2007. View at Google Scholar · View at Scopus
  28. R. E. Marx, Y. Sawatari, M. Fortin, and V. Broumand, “Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment,” Journal of Oral and Maxillofacial Surgery, vol. 63, no. 11, pp. 1567–1575, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. L. Ruggiero, T. B. Dodson, L. A. Assael, R. Landesberg, R. E. Marx, and B. Mehrotra, “American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 5, pp. 2–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. A. A. Khan, G. K. B. Sándor, E. Dore et al., “Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw,” Journal of Rheumatology, vol. 35, no. 7, pp. 1391–1397, 2008, Erratum in “Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw”, Journal of Rheumatology, vol. 35, no. 8, p. 1688, 2008, Erratum in “Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw”, Journal of Rheumatology, vol. 35, no. 10, p. 2084, 2008. View at Google Scholar
  31. S. Khosla, D. Burr, J. Cauley et al., “Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research,” Journal of Bone and Mineral Research, vol. 22, no. 10, pp. 1479–1491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Montebugnoli, L. Felicetti, D. B. Gissi, A. Pizzigallo, G. A. Pelliccioni, and C. Marchetti, “Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 104, no. 4, pp. 473–477, 2007. View at Google Scholar
  33. A. Wutz, E. Biedermann, F. Wanschitz et al., “Treatment results of bisphosphonate-related osteonecrosis of the jaws,” Head & Neck, vol. 30, no. 9, pp. 1224–1230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Biasotto, S. Chiandussi, F. Dore et al., “Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws,” Acta Odontologica Scandinavica, vol. 64, no. 6, pp. 348–354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. L. Ruggiero, J. Fantasia, and E. Carlson, “Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 102, no. 4, pp. 433–441, 2006. View at Google Scholar
  36. R. E. Marx, “Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 5, pp. 107–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Longobardi, R. Boniello, G. Gasparini, I. Pagano, and S. Pelo, “Surgical therapy for osteonecotic lesions of the jaws in patients in therapy with bisphosphonates,” Journal of Craniofacial Surgery, vol. 18, no. 5, pp. 1012–1017, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Pautke, F. Bauer, T. Tischer et al., “Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 3, pp. 471–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. K. E. Fleisher, S. Doty, S. Kottal, J. Phelan, R. G. Norman, and R. S. Glickman, “Tetracycline-guided debridement and cone beam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: a technical note,” Journal of Oral and Maxillofacial Surgery, vol. 66, no. 12, pp. 2646–2653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Williamson, “Surgical management of bisphosphonate induced osteonecrosis of the jaws,” International Journal of Oral & Maxillofacial Surgery, vol. 39, no. 3, pp. 251–255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Ruggiero, J. Gralow, R. E. Marx et al., “Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer,” Journal of Oncology Practice, vol. 2, no. 1, pp. 7–14, 2006. View at Publisher · View at Google Scholar
  42. K. Alons, S. C. Kuijpers, E. de Jong, and J. P. R. van Merkesteyn, “Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 107, no. 2, pp. e1–e7, 2009. View at Google Scholar
  43. British Dental Association, Bisphosphonates Fact File, British Dental Association, London, UK, 2008.
  44. C. A. Migliorati, J. Casiglia, J. Epstein, P. L. Jacobsem, M. A. Siegel, and S. Woo, “Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper,” The Journal of the American Dental Association, vol. 136, no. 12, pp. 1658–1668, 2005, Erratum in “Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper”, The Journal of the American Dental Association, vol. 137, no. 1, p. 26, 2006. View at Google Scholar · View at Scopus
  45. M. Göllner, S. Holst, M. Fenner, and J. Schmitt, “Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: a clinical report,” The Journal of Prosthetic Dentistry, vol. 103, no. 4, pp. 196–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Saussez, R. Javadian, C. Hupin et al., “Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series,” The Laryngoscope, vol. 119, no. 2, pp. 323–329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. C. A. Migliorati, M. M. Schubert, D. E. Peterson, and L. M. Seneda, “Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy,” Cancer, vol. 104, no. 1, pp. 83–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Badros, D. Weikel, A. Salama et al., “Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 945–952, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Anitua, “Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants,” International Journal of Oral & Maxillofacial Implants, vol. 14, no. 4, pp. 529–535, 1999. View at Google Scholar · View at Scopus
  50. E. Anitua, M. Sanchez, G. Orive, and I. Andia, “The potential impact of the preparation rich in growth factors (PRGF) in different medical fields,” Biomaterials, vol. 28, no. 31, pp. 4551–4560, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Molina-Minano, P. Lopez-Jornet, F. Camacho-Alonso, and V. Vicente-Ortega, “Plasma rich in growth factors and bone formation: a radiological and histomorphometric study in New Zealand rabbits,” Brazilian Oral Research, vol. 23, no. 3, pp. 275–280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Anitua, G. Orive, R. Pla, P. Roman, V. Serrano, and I. Andía, “The effects of PRGF on bone regeneration and on titanium implant osseointegration in goats: a histologic and histomorphometric study,” Journal of Biomedical Materials Research A, vol. 91, no. 1, pp. 158–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Mozzati, G. Gallesio, V. Arata, R. Pol, and M. Scoletta, “Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases,” Oral Oncology, vol. 48, no. 5, pp. 469–474, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Bocanegra-Pérez, M. Vicente-Barrero, M. Knezevic et al., “Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw,” International Journal of Oral & Maxillofacial Surgery, vol. 41, no. 11, pp. 1410–1415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Merigo, M. Manfredi, M. Meleti, D. Corradi, and P. Vescovi, “Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report,” Journal of Oral Pathology & Medicine, vol. 34, no. 10, pp. 613–617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Jabbour, M. El-Hakim, P. Mesbah-Ardakani, J. E. Henderson, and R. Albuquerque Jr., “The outcomes of conservative and surgical treatment of stage 2 bisphosphonate-related osteonecrosis of the jaws: a case series,” International Journal of Oral & Maxillofacial Surgery, vol. 41, no. 11, pp. 1404–1409, 2012. View at Publisher · View at Google Scholar · View at Scopus